New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ICE;NYX;BBBY;MDRX;JBL;FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTBBBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Axle (AXL) upgraded to Overweight from Neutral at JPMorgan... Bed Bath & Beyond (BBBY) upgraded to Outperform from Perform at Oppenheimer... DRDGOLD (DRD) upgraded to Neutral from Underweight at JPMorgan... DealerTrack (TRAK) upgraded to Buy from Hold at Stifel... DreamWorks Animation (DWA) upgraded to Buy from Neutral at B. Riley... First Niagara (FNFG) upgraded to Buy from Hold at Jefferies... Fortinet (FTNT) upgraded to Buy from Neutral at Citigroup... Garmin (GRMN) upgraded at RBC Capital... Harmony Gold (HMY) upgraded to Overweight from Neutral at JPMorgan... Invesco (IVZ) upgraded to Positive from Neutral at Susquehanna... Kansas City Southern (KSU) upgraded at Raymond James... McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens... Melco Crown (MPEL) upgraded to Buy from Hold at Union Gaming... Monro Muffler (MNRO) upgraded to Neutral from Reduce at SunTrust... Pier 1 Imports (PIR) upgraded to Outperform from Perform at Oppenheimer... Piper Jaffray (PJC) upgraded to Neutral from Underperform at Macquarie... Randgold (GOLD) upgraded to Overweight from Neutral at JPMorgan... Rockwell Collins (COL) upgraded to Buy from Hold at Argus... Telefonica (TEF) upgraded to Neutral from Underperform at BofA/Merrill... Triumph Group (TGI) upgraded at RBC Capital... Unilever (UL) upgraded to Buy from Underperform at BofA/Merrill... WWE (WWE) upgraded to Neutral from Underperform at Macquarie.
07:43 EDTBBBYOppenheimer upgrades Bed Bath & Beyond, Pier 1 on better macro outlook
Subscribe for More Information
05:37 EDTBBBYBed Bath & Beyond upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
January 20, 2015
09:06 EDTICENYSE completes minority investment in Coinbase
Subscribe for More Information
January 16, 2015
07:13 EDTICEIntercontinentalExchange February volatility elevated into Q4 and outlook
Subscribe for More Information
January 15, 2015
10:19 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
07:20 EDTICENASDAQ may enter energy derivatives market, Reuters reports
Subscribe for More Information
06:09 EDTFOLDAmicus Therapeutics promotes Bradley Campbell to President and COO
Subscribe for More Information
January 14, 2015
10:21 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
07:37 EDTMDRXJPMorgan to hold a conference
Subscribe for More Information
January 13, 2015
10:17 EDTBBBYOptions with decreasing implied volatility
Subscribe for More Information
January 12, 2015
10:15 EDTBBBYOptions with decreasing implied volatility
Options with decreasing implied volatility: NBIX APOL NPSP BBBY INFY JCP MU TIF
07:49 EDTFOLDAmicus Therapeutics sees current cash to fund operations into 2017
Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use